Ionis wins FDA label expansion for potential blockbuster triglycerides indication
Ionis wins FDA label expansion for potential blockbuster triglycerides indication — Endpoints News coverage of biopharma industry developments.
Ionis Pharmaceuticals
Ionis Pharmaceuticals is a leader in RNA-targeted therapeutics, discovering and developing antisense oligonucleotide (ASO) drugs for serious diseases.
Company Info
Sector:Biopharmaceutical
Headquarters:Carlsbad, California, United States
Founded:1989
Website:www.ionispharma.com/
Upcoming Milestones & Key Dates
2026-Q4
Regulatory
Olezarsen FDA decision expected
Clinical Development Pipeline
Olezarsen
Target: ApoC-IIIDonidalorsen
Target: PKLRIONIS-MAPTRx
Target: MAPTRecent News
Leadership Team
Brett Monia
Chief Executive Officer
Elizabeth Hougen
Chief Financial Officer
C. Frank Bennett
Chief Scientific Officer